A Study of Safety and Efficacy of ATI-2173 in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection and in Subjects With Hepatitis D Virus Coinfection

NCT04847440 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

40

Enrollment

INDUSTRY

Sponsor class

Stopped Terminated by the Sponsor

Conditions

Hepatitis B, Chronic
Hepatitis D

Interventions

DRUG: ATI-2173
DRUG: Viread
DRUG: AB-729

Sponsor

Antios Therapeutics, Inc